A Phase 1b, Open-label, Multicenter Study of (BMS-936564) in Combination With Lenalidomide (Revlimid) Plus Low-dose Dexamethasone, or With Bortezomib (Velcade) Plus Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Inclusion Criteria:

- Subjects must have confirmed diagnosis of multiple myeloma with measurable disease
Excluded are subjects with only plasmacytomas, plasma cell leukemia, or non-secretory
myeloma.

- Disease must be assessed within 28 days prior to treatment initiation.

- Subjects must have evidence of relapsed or relapsed/refractory disease.

- Subjects must have received at least 2 prior regimens for multiple myeloma.

- Eastern Cooperative Oncology Group (ECOG) Performance Status 0 - 2.

- Subjects must have received last treatment (ie, chemotherapy, radiotherapy,
biological, immunotherapy or investigational agent [therapeutic or diagnostic]) at
least 14 days prior to treatment initiation.

Exclusion Criteria:

- A serious uncontrolled medical disorder or active infection.

- Current or recent (within 3 months) gastrointestinal disease or condition that could
impact the absorption of orally-administered drug.

- Inability to swallow oral medication.

- Uncontrolled or significant heart disease.

- Any other malignancy, excluding basal or squamous cell carcinoma of the skin,
cervical carcinoma in situ, localized prostate cancer, or superficial bladder cancer
stage 0, from which the subject has not been disease-free for at least 3 years.